| Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma (NCT07761286) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2026-09-30 |
| A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer (NCT07714668) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2026-08-31 |
| A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer (NCT07750041) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2026-08-30 |
| SYS6010 vs Investigator's Choice of Monotherapy in Patients With Recurrent or Metastatic HNSCC (NCT07758621) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2026-08-15 |
| A Multicenter, Open-label, Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics (PK), and Immunogenicity of the Combination Therapy of SYS6026 in the Treatment of Advanced Solid Tumors (NCT07684261) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2026-07-20 |
| A Phase II Clinical Trial Evaluating the Efficacy and Safety of SYS6026 Injection in Participants With HPV16 or 18-related High-grade Cervical Squamous Intraepithelial Lesions (NCT07702656) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2026-07-10 |
| A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (NCT07708753) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2026-07-01 |
| A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC) (NCT07672223) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2026-06-25 |
| SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma (NCT07374549) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2026-06-20 |
| SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma (NCT07526792) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2026-06-20 |
| SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04） (NCT07633873) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2026-06-02 |
| A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC (NCT07376382) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2026-06-01 |
| SYS6006 in Combination With Enlonstobart Injection Versus Enlonstobart Injection in Participants With Advanced Solid Tumors (NCT07622225) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2026-05-29 |
| A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer (NCT07597629) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2026-05-25 |
| A Study of SYS6051 in Subjects With Advanced Solid Tumors (NCT07591285) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2026-05-12 |
| A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer (NCT07406542) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2026-04-01 |
| SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma (NCT07417735) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2026-03-18 |
| SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ (NCT07442565) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2026-03-10 |
| Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above (NCT07354659) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2026-01-10 |
| A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma. (NCT07251062) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2025-12-30 |
| A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer (NCT07256509) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2025-11-30 |
| SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer (NCT07230626) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2025-11-20 |
| SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC (NCT06989671) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2025-08-30 |
| Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors (NCT07122063) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2025-08-11 |
| Safety and Immunogenicity of SYS6017 in Healthy Participants Aged 40 Years or More (NCT06954818) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2025-05-10 |
| A Study of SYS6040 for Injection in Patients With Advanced Solid Tumors (NCT06970795) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2025-04-10 |
| Evaluation of SYS6005 in Patients With Advanced Malignant Tumor (NCT06958679) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2025-04-03 |
| Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01） (NCT06927986) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2025-03-30 |
| A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors (NCT07744763) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2025-03-28 |
| Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors (NCT06775236) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2025-03-20 |
| Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors (NCT07415863) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2024-12-30 |
| A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors (NCT07110883) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2024-08-15 |